Capital Pro-Égaux Inc. (NEX: CPE.H) Announces Litigation Funding Agreement

Tuesday, March 12, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

MORIN-HEIGHTS, QC, March 12, 2019 /CNW Telbec/ - Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique

d'usinage Sinlab Inc. ("Sinlab"), has entered into a Litigation Funding Agreement for the funding of expenses related to the professional negligence action for damages commenced in 2013 in Florida against Sinlab's counsel
who represented Sinlab in litigation in Virginia against certain entities who violated Sinlab's pioneering digital dentistry patent portfolio (the "Litigation").

Update on Litigation

The Litigation continues and is expected to be on the trial docket for the fourth quarter, 2019, with limited additional discovery during the next few months. To date, no defendant has offered any settlement payment to Sinlab.

Litigation Funding Agreement

The Company and Sinlab explored solutions to finance expenses relating to the Litigation, including a temporary revocation of the cease trade order to complete a private placement of common shares and funding from commercial litigation financing entities.

Ultimately, Sinlab entered into a litigation funding agreement with certain of its directors and officers upon terms and conditions consistent with those available from commercial litigation financing entities. The agreement provides for funding of litigation expenses in exchange for the payment of a portion of the proceeds from the resolution of the Litigation, including a settlement or a judgement, ranging between 20% and 40% depending on the amount of funding expended and timing of the resolution of the Litigation. In order not to hurt Sinlab's position in the Litigation, the amount of the funding is not disclosed. However, this amount is in the range of half a million dollars. Although the transaction constitutes a related party transaction of the Company within the meaning of applicable securities legislation, the Company is relying on certain exemptions from the formal valuation and minority approval requirements contained in such legislation.

"The principals of the Company are committed to seeing this Litigation through and are open to considering further financing if necessary" said Mr. Pierre Désormeau, president of the Company.

Caution regarding forward-looking statements

This news release contains certain forward-looking statements regarding the Company's expectation of future events, including potential claims and developments regarding legal proceedings. Such expectations are based on certain assumptions based on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could lead actual results to differ include, amongst others, factors that may impact claims and legal proceedings, such as interpretation of factual matters, time and money involved in undertaking legal proceedings, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by securities laws.

About Pro-Égaux Inc.

Pro-Égaux through its wholly owned subsidiary, Technique d'usinage Sinlab Inc., is a company based in Lachenaie, Quebec, specializing mainly in the conception and design of titanium products to be used in the dental prosthesis restoration industry.

Neither NEX, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of NEX and the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE Capital Pro-Égaux Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store